Prostate CancerCHAMPNCT02613273
CHAMP: A Randomized Controlled Trial of High-intensity Aerobic and Resistance Exercise for Metastatic Prostate Cancer
A study testing Experimental: Arm 1 (Aerobic Exercise) and Experimental: Arm 2 (Resist. Exercise) in people with Prostate Cancer, run by University of California, San Francisco at 1 site in United States.
Trial summary
This Phase II, open-label, three-arm randomized controlled trial (RCT) will investigate the effects of 12 weeks of aerobic exercise vs. 12 weeks of resistance exercise vs. usual care in men with metastatic castration resistant prostate cancer to determine the safety, feasibility, and tolerance of exercise; quality of… Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Prostate Cancer
- What is being tested?
- Experimental: Arm 1 (Aerobic Exercise) and Experimental: Arm 2 (Resist. Exercise)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 28 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Jul 2016to 30 Jun 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically documented adenocarcinoma of the prostate with systemic bone or node metastatic disease despite castrate levels of testosterone (<50 ng/dL) due to orchiectomy or luteinising hormone-releasing hormone (LHRH) agonist. Castrate levels of testosterone must be maintained while on study. Men can be enrolled prior to starting abiraterone and/or enzalutamide OR already be receiving treatment with abiraterone and/or enzalutamide.
- On androgen deprivation therapy (ADT) with a Gonadotropin-releasing hormone (GnRH) agonist/antagonist or prior bilateral orchiectomy. All patients will be required to be on ADT throughout the study.
- ≥4 weeks since any major surgery and fully recovered
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Required Initial Laboratory Values:
- Platelet count ≥ 100,000/microliter (uL)
Show all 11Show fewer
- Hepatic and renal dysfunction that would preclude participation in an exercise program, in the opinion of the treating physician
- Serum testosterone ≤ 50 ng/dL
- Medical clearance to undergo steep ramp test and completion of steep ramp test
- Physician consent to participate in vigorous aerobic or resistance exercise training
- Age ≥18 years
Who cannot join
- Men with small cell neuroendocrine tumors or features of small cell disease
- Chemotherapy criteria: Metastatic castrate-resistant prostate cancer (CRPC) pre-chemo (metastatic castration-resistant adenocarcinoma prostate cancer, pre-CRPC chemotherapy), which is given for hormone-sensitive prostate cancer, is allowed. Metastatic CRPC post- chemo (metastatic castrate-resistant adenocarcinoma prostate cancer, post-CRPC chemotherapy) is allowed with the treating physician's (oncologist) discretion/approval.
- Poorly controlled hypertension
- Any contraindications to vigorous exercise, including, but not limited to: brain metastases, current congestive heart failure, serious or non-healing wound, and no serious cardiovascular events within 12 months
- Experiences shortness of breath, chest discomfort, or palpitations when performing activities of daily living (can participate with cardiologist clearance)
- Has difficulty climbing a flight of stairs due to physical impairment
Show all 17Show fewer
- Has been recommended by a doctor to only medically supervised activity
- Has chest pain brought on by physical activity (can participate with cardiologist clearance)
- Has developed chest pain in the past month (can participate with cardiologist clearance)
- Serious or non-healing wound, ulcer, or bone fracture
- Spinal cord compromise or instrumentation due to metastatic disease. Radiation therapy for metastatic disease is allowed.
- Serious or non-healing wound, ulcer, or bone fracture.
- Spinal cord compromise or instrumentation due to metastatic disease. Radiation therapy for metastatic disease is allowed.
- Any peripheral neuropathy ≥grade 3
- Moderate-to-severe bone pain (i.e., National Cancer Institute's Common Terminology Criteria for Adverse Events grade 2-3 bone pain).
- Men participating in vigorous aerobic exercise for 75 minutes or more per week and/or resistance exercise three or more days per week
- Men who do not complete the baseline lifestyle and quality-of-life questionnaires
Trial locations and contacts
1 site in 1 country.
United States1 site
University of California, San Francisco
San Francisco, California, 94143
About this study
This Phase II, open-label, three-arm randomized controlled trial (RCT) will investigate the effects of 12 weeks of aerobic exercise vs. 12 weeks of resistance exercise vs. usual care in men with metastatic castration resistant prostate cancer to determine the safety, feasibility, and tolerance of exercise; quality of life indicators, and a prognostic score.
Read the detailed description
This is a PI-initiated, randomized clinical trial of 12 weeks of aerobic exercise vs. 12 weeks of resistance exercise vs. usual care among 39 men with metastatic castration resistant prostate cancer. Eligible men will be randomized with equal probability to one of the three regimens. All patients will receive a packet of print material on diet, exercise, and psycho-social support appropriately geared for men with late stage disease at the end of the trial. The aerobic exercise arm (N=13) will receive a 3 day/week remotely-supervised exercise regimen that includes high-intensity interval training and continuous vigorous intensity aerobic exercise training. The resistance exercise arm (N=13) will receive a 3 day/week remotely-supervised resistance exercise regimen incorporating different volumes and loads. Men in the control arm (N=13) will be asked to continue their typical exercise practices for 12 weeks. Subjects will be asked to complete questionnaires, physical function and strength tests, body measurements, and collection of blood specimen at baseline and 12 weeks.
- Conditions
- Prostate Cancer
- Being tested
- Experimental: Arm 1 (Aerobic Exercise), Experimental: Arm 2 (Resist. Exercise)
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Experimental: Arm 1 (Aerobic Exercise)Behavioural
This periodized program consists of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout.
Experimental: Arm 2 (Resist. Exercise)Behavioural
This periodized program consisting of 3 resistance exercise sessions per week comprised of high load/low volume, light load/high volume, and moderate load/moderate volume.
| Study group | Role | What they receive |
|---|---|---|
| Experimental: Arm 1 (Aerobic Exercise) | Experimental | Arm 1 will engage in a periodized program consisting of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months. Receives: Behavioral: Experimental: Arm 1 (Aerobic Exercise) |
| Experimental: Arm 2 (Resist. Exercise) | Experimental | Arm 2 will engage in a periodized program consisting of 3 resistance exercise sessions per week comprised of various loads and volumes. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months. Receives: Behavioral: Experimental: Arm 2 (Resist. Exercise) |
| No Intervention: Arm 3 (Control) | No intervention | Arm 3 will follow their usual exercise and lifestyle routine. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of self-reported adverse events by arm
Adverse events will be assessed at each weekly coach call, at clinic visits during the study, and at the 12-week study visit. They are continuously reported from informed consent until 28 days after the 12-week study visit.
Measured: Up to 4 months
Attendance at 70% or more of exercise sessions.
Study feasibility will be determined by the proportion of participants who complete 70 percent or more of all sessions.
Measured: 3 months
Adherence at 70% or more of the completed exercise sessions.
Study feasibility will be determined by the proportion of participants who completed 70 percent or more of the exercise sessions as or more than prescribed.
Measured: 3 months
Median sessional tolerance
Exercise tolerance will be assessed by participant self-report of a single question at each exercise session using a 10 point Likert scale with a minimum score of 0=intolerable and a maximum score of 10=highly tolerable.
Measured: Up to 3 months
Study acceptability
Proportion of participants who were satisfied or very satisfied with the intervention
Measured: 3 months
Secondary outcomes (14)
Change in scores on the Fatigue visual analog scale (VAS)
Fatigue will be assessed by participant self-report of a single question at each exercise session using a 10 point Likert scale with a minimum score of 0=no fatigue and a maximum score of 10=maximum fatigue.
Measured: 3 months
Change in scores on the Bone pain visual analog scale (VAS)
Bone pain will be assessed by participant self-report of a single question at each exercise session using a 10 point Likert scale with a minimum score of 0=no bone pain and a maximum score of 10=maximum bone pain.
Measured: Up to 3 months
Number of participants reporting use of opiate pain medication
The World Health Organization (WHO) Analgesic Ladder will be used to record the use of pain medication by participants at each visit. The three main principles of the WHO analgesic ladder are: "By the clock, by the mouth, by the ladder". "By the clock" means to maintain freedom from pain, drugs should be given "by the clock" or "around the clock" rather than only "on demand" (i.e. PRN). "By the mouth" means the oral route is usually the preferred route for ease of use in a variety of care settings. "By the ladder" means opiates have been given if pain occurs there should be prompt administration of drugs in the following order: non-opiates (e. g. acetaminophen), as necessary, mild opiates (e. g. codeine), and then strong opiates (e. g. morphine or hydromorphone) until the patient is free of pain. Use of pain medication using the WHO analgesic ladder will be completed at baseline and 3 months.
Measured: Up to 3 months
Change in Scores on the Brief-Pain Inventory Short Form (BPI-SF)
The BPI-SF is a 9-item questionnaire used to assess the severity of pain and the impact of pain on activities of daily living over a recall period of 24 hours. Pain severity is assessed across four sub-scales; 'worst pain', 'least pain', 'average pain' and 'current pain'. A pain score for each subscale is presented separately. Scales are rated on a scale of 0 to 10 (0 = no pain; 10 = pain as bad as one can imagine). A composite score for pain severity is calculated as the mean of the four severity items. Question 9 comprises a 7-item interference scale. Questions assess the level to which pain interferes with general activity, walking, work, mood, enjoyment of life, relations with others and sleep on a scale of 0 to 10 (0 = does not interfere; 10 = completely interferes). Mean interference score will be calculated as an average of the seven subparts of question 9 where at least four of the seven items are completed. Participants will complete the assessment at baseline and 3 months.
Measured: Up to 3 months
Change in objective physical function over time
Participants objective physical function will be assessed using a combination of the the steep ramp (short maximal exercise test that is performed on a cycle ergometer), repeated chair rise, stair climb, and 400 meter (m) walk.
Measured: Up to 3 months
Change in objective physical strength over time
Strength assessments will comprise one repetition maximum (RM)chest press, leg press and seated row. One method will be chosen as the primary method, based on the availability of resistance equipment however, alternative methods will be used, if not appropriate for the patient based on the location of metastasis. The 1-RM is defined as the highest load that can be lifted through full range of movement at one time. Participant suitability to perform each test will be dependent on the site of the metastasis. The decision to either complete or not complete 1 repetition maximum (RM) testing at each site will be decided by the exercise physiologist / therapist performing the test in consultation with the participant's treating physician using an exercise checklist completed by the physician, prior to any testing, which will indicate which exercises to avoid. Any exercise during testing which causes a participant issues will be stopped.
Measured: Up to 3 months
Change in scores on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) over time
The functional domains measure the quality of life in Physical functioning, Role functioning, Emotional functioning, Cognitive functioning, Social functioning. Scores consists of responses to items with responses ranging from 1="Not at all" to 4="Very Much". The raw score is calculated by estimating the mean of the items that make up each domains with a resulting total range of 1 - 4. These scores are then transformed to standardized scale score, so that scores range from 0 to 100. A high score for the functional domains represents a high level of functioning. Participants will complete the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 at baseline and 3 months.
Measured: Up to 3 months
Change in scores on the EuroQol Five-Dimensional Questionnaire (EQ-5D)
EQ-5D is a standardized instrument for measuring generic health status. The health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The respondents self-rate their level of severity for each dimension by selecting one of the following responses: no problems (0), slight problems (1), mild problems (2), moderate problems (3), or severe problems (4) with a particular dimension. Lower scores indicate less issues/problems with that particular health dimension. Participants will complete the EQ-5D at baseline and 3 months.
Measured: Up to 3 months
Change in scores on the Expanded Prostate Cancer Index Composite-26 (EPIC-26)
The EPIC-26 measures the impact of quality of life issues across 5 prostate cancer specific domains: Urinary incontinence, Urinary irritation, Bowel function, Sexual function, and Hormonal function and overall total quality of life. Response options for each EPIC item form a Likert scale, and the raw score of each item is then transformed linearly to a 0-100 scale. Multiple items are combined and then averaged to form the domain scores and total score at each time point also ranging from 0-100, with higher scores representing better health related quality of life (HRQOL). Participants will complete the EPIC-26 at baseline and 3 months.
Measured: Up to 3 months
Change in scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) is a 13-item measure that assessing the consequences of fatigue and its impact on participants quality of life. Each item is rated on a 5-point Likert scale ranging from 0 = "Not at all" to 4 = "Very much" with a total score range of 0-52, and higher scores indicating a greater impact of fatigue on . Participants will complete the FACIT-F at baseline and 3 months.
Measured: Up to 3 months
Change in scores on the State-Trait Anxiety Inventory for Adults (STAI)
The Spielberger et. al STAI is a commonly used measure of trait and state anxiety. It can be used in clinical settings to diagnose anxiety and to distinguish it from depressive syndromes. It has 20 items for assessing trait anxiety and 20 for state anxiety for a total of 40 items. State anxiety items include: "I am tense; I am worried" and "I feel calm; I feel secure." Trait anxiety items include: "I worry too much over something that really doesn't matter" and "I am content; I am a steady person." All items are rated on a 4-point scale (e.g., from "1=Almost Never" to 4="Almost Always") with a maximum score range of 40-160 when all 40 items are administered Higher scores indicate greater anxiety. Participants will complete the State Anxiety Inventory at baseline and 3 months.
Measured: Up to 3 months
Change in Scores on the Center for Epidemiological Studies Depression Scale (CESD)
The Center for Epidemiological Studies-Depression (CES-D) is a 20-item measure that asks caregivers to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms. Participants will complete the Center for Epidemiological Studies Depression Scale at baseline and 3 months.
Measured: Up to 3 months
Change in scores on the Pittsburgh Sleep Quality Index (PSQI) over time
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score with a possible range of 0-21 points, with lower global scores indicating better sleep overall. Participants will complete the Pittsburgh Sleep Quality Index at baseline and 3 months.
Measured: Up to 3 months
Change in FACT-General (FACT-G) social/family wellbeing domain.
FACT-G SFWB scores range from 0 to 28, with a higher score reflecting better social and familial well-being.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Nov 2015 (estimated)
- Study start18 Jul 2016
- Primary completion31 Mar 2020
- Study completion30 Jun 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 28 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Stacey A Kenfield, ScD, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02613273
- Sponsor's protocol ID
- 155510
- Other IDs
- R21CA184605, NCI-2017-01928
- Acronym
- CHAMP
- Status last verified
- Aug 2022
- First submitted
- 20 Nov 2015
- Last updated
- 12 Aug 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Aug 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CHAMP: A Randomized Controlled Trial of High-intensity Aerobic and Resistance Exercise for Metastatic Prostate Cancer
- ClinicalTrials.gov ID
- NCT02613273
- Acronym / sponsor ID
- CHAMP / 155510
- Conditions
- Prostate Cancer
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 28 participants (actual)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 18 Jul 2016 (actual)
- Primary completion
- 31 Mar 2020 (actual)
- Study completion
- 30 Jun 2022 (actual)
- First posted
- 24 Nov 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This Phase II, open-label, three-arm randomized controlled trial (RCT) will investigate the effects of 12 weeks of aerobic exercise vs. 12 weeks of resistance exercise vs. usual care in men with metastatic castration resistant prostate cancer to determine the safety, feasibility, and tolerance of exercise; quality of life indicators, and a prognostic score.
Detailed description
This is a PI-initiated, randomized clinical trial of 12 weeks of aerobic exercise vs. 12 weeks of resistance exercise vs. usual care among 39 men with metastatic castration resistant prostate cancer. Eligible men will be randomized with equal probability to one of the three regimens. All patients will receive a packet of print material on diet, exercise, and psycho-social support appropriately geared for men with late stage disease at the end of the trial. The aerobic exercise arm (N=13) will receive a 3 day/week remotely-supervised exercise regimen that includes high-intensity interval training and continuous vigorous intensity aerobic exercise training. The resistance exercise arm (N=13) will receive a 3 day/week remotely-supervised resistance exercise regimen incorporating different volumes and loads. Men in the control arm (N=13) will be asked to continue their typical exercise practices for 12 weeks. Subjects will be asked to complete questionnaires, physical function and strength tests, body measurements, and collection of blood specimen at baseline and 12 weeks.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Experimental: Arm 1 (Aerobic Exercise) | Experimental | Behavioral: Experimental: Arm 1 (Aerobic Exercise)Arm 1 will engage in a periodized program consisting of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months. |
| Experimental: Arm 2 (Resist. Exercise) | Experimental | Behavioral: Experimental: Arm 2 (Resist. Exercise)Arm 2 will engage in a periodized program consisting of 3 resistance exercise sessions per week comprised of various loads and volumes. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months. |
| No Intervention: Arm 3 (Control) | No intervention | –Arm 3 will follow their usual exercise and lifestyle routine. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Histologically documented adenocarcinoma of the prostate with systemic bone or node metastatic disease despite castrate levels of testosterone (<50 ng/dL) due to orchiectomy or luteinising hormone-releasing hormone (LHRH) agonist. Castrate levels of testosterone must be maintained while on study. Men can be enrolled prior to starting abiraterone and/or enzalutamide OR already be receiving treatment with abiraterone and/or enzalutamide.
- On androgen deprivation therapy (ADT) with a Gonadotropin-releasing hormone (GnRH) agonist/antagonist or prior bilateral orchiectomy. All patients will be required to be on ADT throughout the study.
- ≥4 weeks since any major surgery and fully recovered
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Required Initial Laboratory Values:
Key exclusion criteria (17 listed)
- Men with small cell neuroendocrine tumors or features of small cell disease
- Chemotherapy criteria: Metastatic castrate-resistant prostate cancer (CRPC) pre-chemo (metastatic castration-resistant adenocarcinoma prostate cancer, pre-CRPC chemotherapy), which is given for hormone-sensitive prostate cancer, is allowed. Metastatic CRPC post- chemo (metastatic castrate-resistant adenocarcinoma prostate cancer, post-CRPC chemotherapy) is allowed with the treating physician's (oncologist) discretion/approval.
- Poorly controlled hypertension
- Any contraindications to vigorous exercise, including, but not limited to: brain metastases, current congestive heart failure, serious or non-healing wound, and no serious cardiovascular events within 12 months
- Experiences shortness of breath, chest discomfort, or palpitations when performing activities of daily living (can participate with cardiologist clearance)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Experimental: Arm 1 (Aerobic Exercise)This periodized program consists of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout. | Behavioural | Experimental: Arm 1 (Aerobic Exercise) |
| Experimental: Arm 2 (Resist. Exercise)This periodized program consisting of 3 resistance exercise sessions per week comprised of high load/low volume, light load/high volume, and moderate load/moderate volume. | Behavioural | Experimental: Arm 2 (Resist. Exercise) |
Primary outcome
Number of self-reported adverse events by arm
Time frame: Up to 4 months
Adverse events will be assessed at each weekly coach call, at clinic visits during the study, and at the 12-week study visit. They are continuously reported from informed consent until 28 days after the 12-week study visit.
Attendance at 70% or more of exercise sessions.
Time frame: 3 months
Study feasibility will be determined by the proportion of participants who complete 70 percent or more of all sessions.
Adherence at 70% or more of the completed exercise sessions.
Time frame: 3 months
Study feasibility will be determined by the proportion of participants who completed 70 percent or more of the exercise sessions as or more than prescribed.
Median sessional tolerance
Time frame: Up to 3 months
Exercise tolerance will be assessed by participant self-report of a single question at each exercise session using a 10 point Likert scale with a minimum score of 0=intolerable and a maximum score of 10=highly tolerable.
Study acceptability
Time frame: 3 months
Proportion of participants who were satisfied or very satisfied with the intervention
14 secondary outcomes
Change in scores on the Fatigue visual analog scale (VAS)
Time frame: 3 months
Change in scores on the Bone pain visual analog scale (VAS)
Time frame: Up to 3 months
Number of participants reporting use of opiate pain medication
Time frame: Up to 3 months
Change in Scores on the Brief-Pain Inventory Short Form (BPI-SF)
Time frame: Up to 3 months
Change in objective physical function over time
Time frame: Up to 3 months
Change in objective physical strength over time
Time frame: Up to 3 months
Change in scores on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) over time
Time frame: Up to 3 months
Change in scores on the EuroQol Five-Dimensional Questionnaire (EQ-5D)
Time frame: Up to 3 months
Change in scores on the Expanded Prostate Cancer Index Composite-26 (EPIC-26)
Time frame: Up to 3 months
Change in scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
Time frame: Up to 3 months
Change in scores on the State-Trait Anxiety Inventory for Adults (STAI)
Time frame: Up to 3 months
Change in Scores on the Center for Epidemiological Studies Depression Scale (CESD)
Time frame: Up to 3 months
Change in scores on the Pittsburgh Sleep Quality Index (PSQI) over time
Time frame: Up to 3 months
Change in FACT-General (FACT-G) social/family wellbeing domain.
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Aug 2022.
- Individual participant dataSharing planned: No
Related trials for Prostate Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stacey A Kenfield, ScD principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Experimental: Arm 1 (Aerobic Exercise) and Experimental: Arm 2 (Resist. Exercise) in people with Prostate Cancer, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of self-reported adverse events by arm (time frame: Up to 4 months). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2022.